| Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination | Abdul Ghafur,Ashwini Tayade,Priyadarshini Kannaian | 79–86 |
| Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey | Sukran Kose,Gursel Ersan,Suheyla Serin Senger,Gulsun Akincioglu,Melda Ulusoy,Gulgun Akkoclu | 87–92 |
| Validation of Peracetic Acid as a Sporicide for Sterilization of Working Surfaces in Biological Safety Cabinets | Sandra R.B.R. Sella,Belquis P. Guizelini,Hindy Ribeiro | 93–99 |
| The Markers Predicting Response to Hepatitis C Virus Treatment and Evaluation of Treatment Responses | Özgür Günal,Hüseyin Şener Barut,Ünal Erkorkmaz | 100–108 |
| In-vitro Activity of Tigecycline against Methicillin-Resistant Staphylococcus aureus Isolated from Wounds of Burn Patients in Tripoli-Libya | Abdulazziz Zorgani,Omar Elahmer,Hisham Ziglam,Khalifa Sifaw Ghenghesh | 109–112 |
| Invasive orbital aspergillosis in an apparently immunocompetent host without evidence sinusitis | Jennifer Primeggia,George Cyriac,Princy Kumar | 113–116 |
| Two Cases of Hantavirus Infection in Crimean-Congo Haemorrhagic Fever Endemic Region | Mustafa Sunbul,Hava Yılmaz,Hasan Çetinkaya,Yavuz Uyar,Dilek Çaglayık,Fatih Bostancı,Hakan Leblebicioglu | 117–120 |
| The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin | Hayati Demiraslan,Zeynep Ture,Aysegul Ulu Kılıc | 121–123 |
| Sexual dysfunction in male patients with pulmonary tuberculosis | Katerina KULCHAVENYA,Maxim Scherban,Lena Brizhatyuk,Alexander Osadchiy | 124–126 |
| Emergence of linezolid resistant Staphylococcus aureus in Bastar tribal region, India | Mohammad Fareed Khan,Arvind Neral,Vikas Chandra Yadav,Farah Aziz Khan,Sarfaraz Ahmed | — |